Freitag Frederick G, Shumate Derrick
Department of Neurology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI, 53226, USA,
CNS Drugs. 2014 Oct;28(10):921-7. doi: 10.1007/s40263-014-0202-2.
There are only a handful of drugs that have been submitted for and received an indication for the preventative treatment of migraine by the US Food and Drug Administration, as well as international governmental regulatory agencies. However, there are a wide variety of agents that are used for this indication with different levels of evidence for efficacy and tolerability. Several guidelines have been published in recent years examining the evidence-based medicine of migraine preventative therapy and these provide guidance especially for the primary care clinician, but also for neurologists whose primary focus is not headache medicine. Some of the therapies are used in children and adolescents while others are used more commonly in adults. In the adult population, an evolutive state of migraine is more commonly seen than in young persons, that is chronic migraine. There is a paucity of evidence for medications for this stage of migraine but there is a single agent that is approved for this use but not for use in the treatment of episodic migraine. There have been few advances in the field of migraine-preventative medications in recent years but potential novel approaches are in development.
只有少数几种药物已提交给美国食品药品监督管理局以及国际政府监管机构，并获得了偏头痛预防性治疗的适应症。然而，有各种各样的药物用于这一适应症，其疗效和耐受性的证据水平各不相同。近年来，已经发布了几项指南，探讨偏头痛预防性治疗的循证医学，这些指南不仅为初级保健临床医生提供指导，也为主要关注非头痛医学的神经科医生提供指导。有些疗法用于儿童和青少年，而其他疗法在成人中更常用。在成人人群中，偏头痛的一种演变状态比年轻人更常见，即慢性偏头痛。对于偏头痛这一阶段的药物治疗，证据很少，但有一种单一药物被批准用于此用途，但不用于治疗发作性偏头痛。近年来，偏头痛预防性药物领域进展甚微，但潜在的新方法正在研发中。
